Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

November 14, 2019

Tiffany A. Traina, MD, discusses emerging therapies for the management of metastatic triple-negative breast cancer.

November 14, 2019

Isabel Preeshagul, DO, MBS, discusses encouraging updates with molecular drivers in non–small cell lung cancer and her advice to community oncologists treating patients.

November 13, 2019

Mark G. Kris, MD, discusses the ongoing search for additional biomarkers in advanced squamous non­–small cell lung cancer.

November 12, 2019

Komal Jhaveri, MD, FACP, discusses updates in research for metastatic HR-positive, HER2-negative breast cancer.

November 12, 2019

Michael D. Offin, MD, discusses targeted agents in MET- and RET-altered non–small cell lung cancer.

November 11, 2019

The use of immunotherapy, either as monotherapy or in combination with chemotherapy, continues to raise the bar with regard to overall survival benefit in patients with newly diagnosed, advanced nonsquamous non–small cell lung cancer.

November 09, 2019

W. Victoria Lai, MD, discusses the results of the phase III CASPIAN trial in small cell lung cancer.

November 08, 2019

Michael D. Offin, MD, discusses ongoing research focusing on some of the less-common targetable mutations in non–small cell lung cancer.

November 08, 2019

Komal Jhaveri, MD, FACP, discusses the use of trastuzumab biosimilars in breast cancer.

November 02, 2019

Sergio A. Giralt, MD, professor of medicine at Weill Cornell Medical College, and chief, Adult Bone Marrow Transplant Service, Melvin Berlin Family Chair in Multiple Myeloma, at Memorial Sloan Kettering Cancer Center, discusses transplant eligibility criteria in multiple myeloma.

November 01, 2019

Jae H. Park, MD, discusses encouraging data with CAR T-cell therapy in acute lymphoblastic leukemia.

November 01, 2019

Anthony R. Mato, MD, MSCE, discusses the introduction of rituximab biosimilars in chronic lymphocytic leukemia.

November 01, 2019

OncLive interviewed experts at the State of the Science Summits™ in October 2019 on what they wish more people knew in community practice that is not yet widespread.

November 01, 2019

Overall, compelling response rates and rates of conversion to resection for patients with initially unresectable colorectal liver metastases treated with hepatic arterial infusion suggest consideration of earlier initiation of the technique in chemotherapy-naïve patients as well as its adoption in patients who have failed first-line systemic chemotherapy before proceeding to second- or third-line regimens.

November 01, 2019

Ghassan K. Abou-Alfa, MD, discusses the results of the phase III ClarIDHy trial in advanced cholangiocarcinoma.

October 31, 2019

W. Victoria Lai, MD, discusses the impact immunotherapy has had in the management of patients with extensive-stage small cell lung cancer.

October 30, 2019

Gregory J. Riely, MD, PhD, discusses the current treatment landscape for ALK- and ROS1-positive non–small cell lung cancer.

October 29, 2019

Treatment with iodine-131 apamistamab led to a high bone marrow transplant rate compared with salvage chemotherapy in elderly patients with relapsed/refractory acute myeloid leukemia.

October 29, 2019

Mark E. Robson, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the driving force behind biosimilar use in oncology.

October 28, 2019

MCLA-128, an investigational bispecific HER2/HER3 antibody, demonstrated radiological and clinical responses in patients with metastatic pancreatic ductal adenocarcinoma and metastatic non–small cell lung cancer who have NRG1 fusions.